Clinical Trial Update: Orelabrutinib in Combination With Thiotepa in Refractory and Relapsed Primary CNS Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial evaluating orelabrutinib in combination with thiotepa for refractory and relapsed primary CNS lymphoma (PCNSL) across Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cns Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Orelabrutinib (orelabrutinib)
• THIOTEPA (THIOTEPA)

Snippet

Sponsor: Huiqiang Huang | Conditions: Refractory and Relapsed Primary CNS Lymphoma, PCNSL | Phase 1, Phase 2 | Status: UNKNOWN